PatientInitialsName
Item
Patient Initials
text
C25191 (NCI Thesaurus ValueDomain)
C1547383 (UMLS 2011AA ValueDomain)
C16960 (NCI Thesaurus ObjectClass)
C0030705 (UMLS 2011AA ObjectClass)
C25536 (NCI Thesaurus Property)
C1555582 (UMLS 2011AA Property)
ProtocolCoordinatingIdentifierNumber
Item
Study#
text
C25337 (NCI Thesaurus ValueDomain)
C0237753 (UMLS 2011AA ValueDomain)
C25320 (NCI Thesaurus ObjectClass)
C1507394 (UMLS 2011AA ObjectClass)
C25462 (NCI Thesaurus Property)
C0700114 (UMLS 2011AA Property)
C25364 (NCI Thesaurus Property)
C0600091 (UMLS 2011AA Property)
NCIInstitutionIdentifierCode
Item
Site#
text
C25162 (NCI Thesaurus ValueDomain)
C0805701 (UMLS 2011AA ValueDomain)
C21541 (NCI Thesaurus ObjectClass)
C0018704 (UMLS 2011AA ObjectClass)
C25364 (NCI Thesaurus Property)
C0600091 (UMLS 2011AA Property)
C19202 (NCI Thesaurus ObjectClass)
C1513882 (UMLS 2011AA ObjectClass)
PatientCoordinatingIdentifierNumber
Item
ID#
text
C25337 (NCI Thesaurus ValueDomain)
C0237753 (UMLS 2011AA ValueDomain)
C16960 (NCI Thesaurus ObjectClass)
C0030705 (UMLS 2011AA ObjectClass)
C25462 (NCI Thesaurus Property)
C0700114 (UMLS 2011AA Property)
C25364 (NCI Thesaurus Property)
C0600091 (UMLS 2011AA Property)
Dateofassessment
Item
Visit Date
text
Item
Does the patient have biopsy proven KS involving the skin, lymph nodes, oral cavity, gastrointestinal (GI) tract and/or lungs?
text
Code List
Does the patient have biopsy proven KS involving the skin, lymph nodes, oral cavity, gastrointestinal (GI) tract and/or lungs?
Item
Does the patient have Serologic documentation of HIV infection 21 days prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test?
text
Code List
Does the patient have Serologic documentation of HIV infection 21 days prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test?
Item
Is patient's baseline Karnofsky performance status >60%?
text
Code List
Is patient's baseline Karnofsky performance status >60%?
Item
Is patient's hemoglobin > 8 g/dl within 7 days of study entry?
text
Code List
Is patient's hemoglobin > 8 g/dl within 7 days of study entry?
Item
Is patient's absolute neutrophil count > 1500 cells/mm3 and platelets > 100,000 cells/mm3 within 7 days of study entry?
text
Code List
Is patient's absolute neutrophil count > 1500 cells/mm3 and platelets > 100,000 cells/mm3 within 7 days of study entry?
Item
Is patient's creatinine < 1.5 times the upper limit of normal within 7 days of study entry?
text
Code List
Is patient's creatinine < 1.5 times the upper limit of normal within 7 days of study entry?
Item
Is patient's total bilirubin <1.5x ULN within 7 days of study entry?
text
Code List
Is patient's total bilirubin <1.5x ULN within 7 days of study entry?
Item
Is patient's AST (SGOT) and ALT (SGPT) < 3 x the upper limit of normal within 7 days of study entry?
text
Code List
Is patient's AST (SGOT) and ALT (SGPT) < 3 x the upper limit of normal within 7 days of study entry?
Item
Is patient's life expectancy > 3 months?
text
Code List
Is patient's life expectancy > 3 months?
Item
Is the patient age of 18 or older?
text
Code List
Is the patient age of 18 or older?
Item
Does the patient have ability and willingness to give informed consent?
text
Code List
Does the patient have ability and willingness to give informed consent?
Item
If female capable of childbearing, has the patient had a negative serum B-HCG within 72 hours prior to study entry?
text
Code List
If female capable of childbearing, has the patient had a negative serum B-HCG within 72 hours prior to study entry?
Item
If female capable of childbearing, does the patient agree to practice adequate birth control to prevent pregnancy while receiving treatment and for three months after treatment is discontinued?
text
Code List
If female capable of childbearing, does the patient agree to practice adequate birth control to prevent pregnancy while receiving treatment and for three months after treatment is discontinued?
Item
If female, is the patient breast feeding?
text
Code List
If female, is the patient breast feeding?
Item
If male of child fathering potential, does the patient agree to practice adequate birth control?
text
Code List
If male of child fathering potential, does the patient agree to practice adequate birth control?
Item
In the opinion of the investigator, is the patient capable of complying with the protocol?
text
Code List
In the opinion of the investigator, is the patient capable of complying with the protocol?
Item
If patient is receiving antiretroviral therapy, is the patient on a stable regimen for at least 4 weeks prior to study entry?
text
Code List
If patient is receiving antiretroviral therapy, is the patient on a stable regimen for at least 4 weeks prior to study entry?
Item
Does the patient have concurrent, acute, active opportunistic infection other than oral thrush or genital herpes within 14 days of enrollment?
text
Code List
Does the patient have concurrent, acute, active opportunistic infection other than oral thrush or genital herpes within 14 days of enrollment?
Item
Does the patient have symptomatic visceral Kaposi's Sarcoma requiring cytotoxic therapy unless the patient has already been shown to be refractory to or intolerant of all currently approved agents for visceral Kaposi's Sarcoma?
text
Code List
Does the patient have symptomatic visceral Kaposi's Sarcoma requiring cytotoxic therapy unless the patient has already been shown to be refractory to or intolerant of all currently approved agents for visceral Kaposi's Sarcoma?
Item
Does the patient have concurrent neoplasia requiring cytotoxic therapy?
text
Code List
Does the patient have concurrent neoplasia requiring cytotoxic therapy?
Item
Has the patient had acute treatment for an infection (other than oral thrush or genital herpes) or other serious medical illness within 14 days of study entry?
text
Code List
Has the patient had acute treatment for an infection (other than oral thrush or genital herpes) or other serious medical illness within 14 days of study entry?
Item
Has the patient had anti-neoplastic treatment for Kaposi's Sarcoma (including chemotherapy, radiation therapy, local therapy, biological therapy, or investigational therapy) within two weeks of study entry?
text
Code List
Has the patient had anti-neoplastic treatment for Kaposi's Sarcoma (including chemotherapy, radiation therapy, local therapy, biological therapy, or investigational therapy) within two weeks of study entry?
Item
Has the patient had previous local therapy of any KS-indicator lesion within 60 days unless the lesion has clearly progressed since treatment?
text
Code List
Has the patient had previous local therapy of any KS-indicator lesion within 60 days unless the lesion has clearly progressed since treatment?
Item
Has the patient used of investigational drugs other than IND-available anti-retroviral agents?
text
Code List
Has the patient used of investigational drugs other than IND-available anti-retroviral agents?
Item
Does the patient have evidence of a prior MI or cardiac ischemia?
text
Code List
Does the patient have evidence of a prior MI or cardiac ischemia?